Bristol-Myers Squibb Company (BMY) Q4 2018 Earnings Results

Bristol Myers Squibb Beats on EPS, Stock Down 1.88%

Bristol Myers Squibb's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. However, the stock reacted negatively, declining by 1.88%, possibly due to a lack of revenue data and no guidance for the future. Investors may be cautious as they await more information on the company's performance and outlook.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.94	N/A	+3.11%

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in their strategic direction. They acknowledged challenges but remained focused on delivering value.

Management highlighted the continued strength of their product pipeline.

They emphasized a focus on innovation and long-term growth.

Bristol Myers Squibb Beats on EPS, Stock Down 1.88%

Key numbers

Management commentary

Bristol-Myers Squibb Company

More earnings this week

Bristol Myers Squibb Beats on EPS, Stock Down 1.88%

Key numbers

Management commentary